Rohto PharmaceuticalLtd Management

Management criteria checks 4/4

Rohto PharmaceuticalLtd's CEO is Yamada Kunio, appointed in Jun 2009, has a tenure of 15.17 years. total yearly compensation is ¥205.00M, comprised of 89.3% salary and 10.7% bonuses, including company stock and options. directly owns 1.74% of the company’s shares, worth ¥12.69B. The average tenure of the management team and the board of directors is 2.4 years and 5.2 years respectively.

Key information

Yamada Kunio

Chief executive officer

JP¥205.0m

Total compensation

CEO salary percentage	89.3%
CEO tenure	15.2yrs
CEO ownership	1.7%
Management average tenure	2.4yrs
Board average tenure	5.2yrs

Recent management updates

Recent updates

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Jul 11

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Jun 23

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Jun 10

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

May 14

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Apr 03

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Mar 21

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Mar 07

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Feb 26

CEO Compensation Analysis

How has Yamada Kunio's remuneration changed compared to Rohto PharmaceuticalLtd's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	JP¥30b
Mar 31 2024	n/a	n/a	JP¥31b
Dec 31 2023	n/a	n/a	JP¥31b
Sep 30 2023	n/a	n/a	JP¥30b
Jun 30 2023	n/a	n/a	JP¥28b
Mar 31 2023	JP¥205m	JP¥183m	JP¥26b
Dec 31 2022	n/a	n/a	JP¥26b
Sep 30 2022	n/a	n/a	JP¥23b
Jun 30 2022	n/a	n/a	JP¥23b
Mar 31 2022	JP¥196m	JP¥178m	JP¥21b
Dec 31 2021	n/a	n/a	JP¥23b
Sep 30 2021	n/a	n/a	JP¥21b
Jun 30 2021	n/a	n/a	JP¥20b
Mar 31 2021	JP¥185m	JP¥176m	JP¥17b
Dec 31 2020	n/a	n/a	JP¥14b
Sep 30 2020	n/a	n/a	JP¥14b
Jun 30 2020	n/a	n/a	JP¥15b
Mar 31 2020	JP¥192m	JP¥179m	JP¥15b
Dec 31 2019	n/a	n/a	JP¥11b
Sep 30 2019	n/a	n/a	JP¥10b
Jun 30 2019	n/a	n/a	JP¥9b
Mar 31 2019	JP¥181m	JP¥173m	JP¥10b

Compensation vs Market: Yamada's total compensation ($USD1.40M) is about average for companies of similar size in the JP market ($USD1.15M).

Compensation vs Earnings: Yamada's compensation has been consistent with company performance over the past year.

CEO

Yamada Kunio (68 yo)

15.2yrs

Tenure

JP¥205,000,000

Compensation

Mr. Yamada Kunio had been the President at Rohto Pharmaceutical Co. Ltd. since June 9, 2009 until 2019. Mr. Kunio has been the Chairman of the Board of Directors and Representative Director at Rohto Pharma...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yamada Kunio	Chairman of the Board & CEO	15.2yrs	JP¥205.00m	1.74% ¥ 12.7b
Masashi Sugimoto	President & Representative Director	5.2yrs	no data	0.0075% ¥ 54.2m
Saito Masaya	EVP, CFO & Director	2.4yrs	no data	0.021% ¥ 149.8m
Shinichi Kunisaki	EVP, CTO & Director	2.4yrs	no data	0.018% ¥ 130.7m
Hideto Kamimura	Senior Executive Officer and General Manager of Marketing Division	no data	no data	0.0053% ¥ 38.3m
Yasunori Kawasaki	CHRO & Director	1.2yrs	no data	no data
Hidetoshi Segi	MD, Chief Strategy Officer & Director	2.4yrs	no data	0.0039% ¥ 28.7m

2.4yrs

Average Tenure

63.5yo

Average Age

Experienced Management: 4527's management team is considered experienced (2.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Yamada Kunio	Chairman of the Board & CEO	25.2yrs	JP¥205.00m	1.74% ¥ 12.7b
Masashi Sugimoto	President & Representative Director	5.2yrs	no data	0.0075% ¥ 54.2m
Saito Masaya	EVP, CFO & Director	13.2yrs	no data	0.021% ¥ 149.8m
Shinichi Kunisaki	EVP, CTO & Director	14.2yrs	no data	0.018% ¥ 130.7m
Yasunori Kawasaki	CHRO & Director	1.2yrs	no data	no data
Hidetoshi Segi	MD, Chief Strategy Officer & Director	6.2yrs	no data	0.0039% ¥ 28.7m
Kimura Masanori	Standing Corporate Auditor	8.2yrs	no data	0.027% ¥ 194.5m
Akie Iriyama	Independent Outside Director	5.2yrs	no data	no data
Haruka Mera	Independent Outside Director	4.2yrs	no data	no data
Tatsuo Uemura	Independent Outside Director	2.2yrs	no data	0.00044% ¥ 3.2m
Eriko Hayashi	Independent Outside director	2.2yrs	no data	no data
Maiko Katadae	Independent Outside Director	less than a year	no data	no data

5.2yrs

Average Tenure

63yo

Average Age

Experienced Board: 4527's board of directors are considered experienced (5.2 years average tenure).

Rohto PharmaceuticalLtd Management

Management criteria checks 4/4

Key information

Recent management updates

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023

Less than half of directors are independent

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2022

Less than half of directors are independent

Recent updates

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Rohto Pharmaceutical Co.,Ltd. Revises Dividend Guidance for the Second Quarter-End and Full Fiscal Year Ending March 31, 2025

Investor sentiment deteriorates as stock falls 16%

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Final dividend of JP¥15.00 announced

Now 20% undervalued

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Aug 07, 2024

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Rohto Pharmaceutical Co.,Ltd. agreed to acquire 51% stake in Mono chem-pharm Produkte Gmbh for €30 million.

Now 21% undervalued after recent price drop

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

Rohto Pharmaceutical Co.,Ltd. to Report Q4, 2024 Results on May 13, 2024

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million.

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Upcoming dividend of JP¥15.00 per share

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Now 21% undervalued after recent price drop

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Third quarter 2024 earnings released: EPS: JP¥41.92 (vs JP¥37.02 in 3Q 2023)

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Feb 09, 2024

Price target decreased by 7.5% to JP¥3,814

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 31, 2024, Payable on December 7, 2023

Price target increased by 9.4% to JP¥4,126

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023

Upcoming dividend of JP¥12.00 per share at 0.6% yield

Price target increased by 9.4% to JP¥3,999

Price target increased by 9.0% to JP¥3,884

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Aug 09, 2023

Price target decreased by 13% to JP¥3,206

Full year 2023 earnings: EPS exceeds analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023

Price target increased by 27% to JP¥3,531

Price target increased by 8.4% to JP¥2,870

Upcoming dividend of JP¥12.00 per share at 0.9% yield

Rohto Pharmaceutical Co.,Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Third quarter 2023 earnings: Revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Feb 13, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2023 Results on Nov 10, 2022

Upcoming dividend of JP¥20.00 per share

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2023 Results on Aug 09, 2022

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2022

Consensus forecasts updated

Less than half of directors are independent

Rohto Pharmaceutical Co.,Ltd. to Report Fiscal Year 2022 Results on May 12, 2022

Price target increased to JP¥4,325

Now 21% undervalued

Upcoming dividend of JP¥21.00 per share

Now 20% undervalued

Price target increased to JP¥4,175

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2022